46 results on '"Dutko, Frank J."'
Search Results
2. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
3. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
4. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
5. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
6. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3
7. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
8. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials
9. A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273
10. Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
11. Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial
12. Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
13. Drugs as Molecular Tools
14. Crystallographic and Pharmacological Studies of Antiviral Agents Against Human Rhinovirus
15. Structural Analysis of a Series of Antiviral Agents Complexed with Human Rhinovirus 14
16. Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound
17. Quantitative Structure–Activity Relationships and Biological Consequences of Picornavirus Capsid-Binding Compounds
18. Letters
19. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A):two randomised, phase 2, open-label trials
20. Antiviral Compounds Bind to a Specific Site Within Human Rhinovirus
21. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
22. Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial
23. The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis
24. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials
25. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial
26. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
27. Chemotherapeutics
28. Keto/Enol Epoxy Steroids as HIV-1 Tat Inhibitors: Structure-Activity Relationships and Pharmacophore Localization
29. Cyclic Variations of 3-Quinolinecarboxamides and Effects on Antiherpetic Activity
30. The structure of coxsackievirus B3 at 3.5 å resolution
31. 3-Pyridines as replacements for an isoxazole ring: The antirhinoviral activity of pyridine analogues related to disoxaril
32. Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism
33. An Evaluation of the Antirhinoviral Activity of Acylfuran Replacements for 3-Methylisoxazoles. Are 2-Acetylfurans Bioisosteres for 3-Methylisoxazoles? [Erratum to document cited in CA122:31229]
34. An Evaluation of the Antirhinoviral Activity of Acylfuran Replacements for 3-Methylisoxazoles. Are 2-Acetylfurans Bioisosteres for 3-Methylisoxazoles?
35. Oxadiazoles as Ester Bioisosteric Replacements in Compounds Related to Disoxaril. Antirhinovirus Activity
36. Human Rhinovirus 14 Complexed with Fragments of Active Antiviral Compounds
37. The structure of human rhinovirus 16
38. Keto/enol epoxy steroids: a new structural class of HIV-1 tat inhibitors
39. A Comparison of the Anti-rhinoviral Drug Binding Pocket in HRV14 and HRV1A
40. Conformationally restricted analogs of disoxaril: a comparison of the activity against human rhinovirus type 14 and 1A
41. CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14. [Erratum to document cited in CA116(15):143280r]
42. A model for compounds active against human rhinovirus-14 based on x-ray crystallography data
43. Immunopathogenesis of human immunodeficiency virus infection in the central nervous system.
44. Crystal structure of human rhinovirus serotype 1A (HRV1A)
45. Three-dimensional structures of drug-resistant mutants of human rhinovirus 14
46. 14 - Quantitative Structure–Activity Relationships and Biological Consequences of Picornavirus Capsid-Binding Compounds
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.